Skip to main content
Erschienen in: International Journal of Clinical Oncology 6/2014

01.12.2014 | Original Article

Tamoxifen versus tamoxifen plus doxorubicin and cyclophosphamide as adjuvant therapy for node-positive postmenopausal breast cancer: results of a Japan Clinical Oncology Group Study (JCOG9401)

verfasst von: Tadahiko Shien, Hiroji Iwata, Kenjiro Aogi, Takashi Fukutomi, Kenichi Inoue, Takayuki Kinoshita, Masato Takahashi, Akira Matsui, Taro Shibata, Haruhiko Fukuda

Erschienen in: International Journal of Clinical Oncology | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Cancer subtype has recently become an increasingly important consideration when deciding the treatment strategy for breast cancer. For the estrogen receptor positive (ER+) subtype, the efficacy of adjuvant endocrine therapy is definitive, but that of adjuvant chemotherapy is controversial.

Methods

In order to evaluate the effect of adding doxorubicin (A) and cyclophosphamide (C) to tamoxifen (TAM) (ACT) on the overall survival (OS) of node-positive postmenopausal breast cancer (PMBC) patients, we conducted a randomized trial. Eligibility criteria included pathologically node-positive (n = 1–9) PMBC, stage I–IIIA disease. Patients were randomized to receive either TAM (20 mg daily) for 2 years or A (40 mg/m2) and C (500 mg/m2) plus TAM (ACT) as adjuvant therapy following surgery.

Results

One hundred twenty-nine patients were recruited (TAM 64, ACT 65) between October 1994 and July 1999. The hazard ratios for OS and relapse-free survival (RFS) were 0.58 (95 % CI 0.24–1.39; log-rank p = 0.22) and 0.45 (95 %CI 0.24–0.86; log-rank p = 0.013), respectively, in favor of ACT. The 5-year OS and RFS were 76.9 % (ER+ 87.1 %, ER− 53.3 %) and 54.9 % (ER+ 59.3 %, ER− 42.9 %) for TAM and 85.0 % (ER+ 90.0 %, ER− 77.1 %) and 76.7 % (ER+ 76.9 %, ER− 76.0 %) for ACT. A higher proportion of the patients receiving ACT than those receiving TAM experienced grade 3 decreased white blood cell count and grade 2–3 nausea.

Conclusion

The efficacy of adding AC to TAM was not high for ER+, node-positive PMBC. However, adjuvant ACT therapy was considered to be effective for ER−, node-positive PMBC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (1990) Treatment of early breast cancer: worldwide evidence in 1985–1990. A systematic overview of all available randomized trials in early breast cancer of adjuvant endocrine and cytotoxic therapy-treatment of early breast cancer, vol 1. Oxford University Press, Oxford, pp 21–49 Early Breast Cancer Trialists’ Collaborative Group (1990) Treatment of early breast cancer: worldwide evidence in 1985–1990. A systematic overview of all available randomized trials in early breast cancer of adjuvant endocrine and cytotoxic therapy-treatment of early breast cancer, vol 1. Oxford University Press, Oxford, pp 21–49
2.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717CrossRef
3.
Zurück zum Zitat Consensus conference (1985) Adjuvant chemotherapy for breast cancer. JAMA 254:3461–3463CrossRef Consensus conference (1985) Adjuvant chemotherapy for breast cancer. JAMA 254:3461–3463CrossRef
4.
Zurück zum Zitat Glick JH, Gelber RD, Goldhirsch A et al (1992) Meeting highlights: adjuvant therapy for primary breast cancer. J Natl Cancer Inst 84:1479–1485PubMedCrossRef Glick JH, Gelber RD, Goldhirsch A et al (1992) Meeting highlights: adjuvant therapy for primary breast cancer. J Natl Cancer Inst 84:1479–1485PubMedCrossRef
5.
Zurück zum Zitat Fisher B, Redmond C, Legault-Poisson S et al (1990) Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the national surgical adjuvant breast and bowel project B-16. J Clin Oncol 8:1005–1018PubMed Fisher B, Redmond C, Legault-Poisson S et al (1990) Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the national surgical adjuvant breast and bowel project B-16. J Clin Oncol 8:1005–1018PubMed
6.
Zurück zum Zitat Tobinai K, Kohno A, Shimada Y et al (1993) Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. Jpn J Clin Oncol 23(4):250–257PubMed Tobinai K, Kohno A, Shimada Y et al (1993) Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. Jpn J Clin Oncol 23(4):250–257PubMed
7.
Zurück zum Zitat Gelber RD, Goldhirsch A (1986) A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 4:1772–1779PubMed Gelber RD, Goldhirsch A (1986) A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 4:1772–1779PubMed
8.
Zurück zum Zitat Boccardo F, Rubagotti A, Amoroso D et al (1992) Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node positive, oestrogen receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA Trial. Eur J Cancer 28:673–680PubMedCrossRef Boccardo F, Rubagotti A, Amoroso D et al (1992) Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node positive, oestrogen receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA Trial. Eur J Cancer 28:673–680PubMedCrossRef
9.
Zurück zum Zitat Pearson OH, Hubay CA, Gordon NH et al (1989) Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor positive breast cancer. Cancer 64:1819–1823PubMedCrossRef Pearson OH, Hubay CA, Gordon NH et al (1989) Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor positive breast cancer. Cancer 64:1819–1823PubMedCrossRef
10.
Zurück zum Zitat Pritchard KI, Paterson AH, Paul NA et al (1996) Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 14(10):2731–2737PubMed Pritchard KI, Paterson AH, Paul NA et al (1996) Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 14(10):2731–2737PubMed
11.
Zurück zum Zitat Pagani O, Gelber S, Simoncini E et al (2009) Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Res Treat 116(3):491–500PubMedCentralPubMedCrossRef Pagani O, Gelber S, Simoncini E et al (2009) Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Res Treat 116(3):491–500PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Fossati R, Confalonieri C, Torri V et al (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16(10):3439–3460PubMed Fossati R, Confalonieri C, Torri V et al (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16(10):3439–3460PubMed
13.
Zurück zum Zitat Fisher B, Anderson S, Tan-Chiu E et al (2001) Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 19(4):931–942PubMed Fisher B, Anderson S, Tan-Chiu E et al (2001) Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 19(4):931–942PubMed
14.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351(9114):1451–1467CrossRef Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351(9114):1451–1467CrossRef
15.
Zurück zum Zitat Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736–1747PubMedCentralPubMedCrossRef Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736–1747PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Paik S, Tang G, Shak S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24(23):3726–3734PubMedCrossRef Paik S, Tang G, Shak S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24(23):3726–3734PubMedCrossRef
17.
Zurück zum Zitat Albain KS, Barlow WE, Shak S et al (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11(1):55–65PubMedCentralPubMedCrossRef Albain KS, Barlow WE, Shak S et al (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11(1):55–65PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Hugh J, Hanson J, Cheang MC et al (2009) Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27:1168–1176 Hugh J, Hanson J, Cheang MC et al (2009) Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27:1168–1176
19.
Zurück zum Zitat Penault-Llorca F, André F, Sagan C et al (2009) Ki-67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27(17):2809–2815PubMedCrossRef Penault-Llorca F, André F, Sagan C et al (2009) Ki-67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27(17):2809–2815PubMedCrossRef
20.
Zurück zum Zitat Niikura N, Iwamoto T, Masuda S et al (2012) Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer. Cancer Sci 103(8):1508–1512PubMedCrossRef Niikura N, Iwamoto T, Masuda S et al (2012) Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer. Cancer Sci 103(8):1508–1512PubMedCrossRef
21.
Zurück zum Zitat Dowsett M, Nielsen TO, A’Hern R et al (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. JNCI. J Natl Cancer Inst 103:1656–1664 Dowsett M, Nielsen TO, A’Hern R et al (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. JNCI. J Natl Cancer Inst 103:1656–1664
Metadaten
Titel
Tamoxifen versus tamoxifen plus doxorubicin and cyclophosphamide as adjuvant therapy for node-positive postmenopausal breast cancer: results of a Japan Clinical Oncology Group Study (JCOG9401)
verfasst von
Tadahiko Shien
Hiroji Iwata
Kenjiro Aogi
Takashi Fukutomi
Kenichi Inoue
Takayuki Kinoshita
Masato Takahashi
Akira Matsui
Taro Shibata
Haruhiko Fukuda
Publikationsdatum
01.12.2014
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 6/2014
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-013-0657-z

Weitere Artikel der Ausgabe 6/2014

International Journal of Clinical Oncology 6/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.